Dimensional Fund Advisors LP Glycomimetics Inc Transaction History

Dimensional Fund Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.55 - $3.49 $59,047 - $80,814	23,156 New	23,156 $69,000
Q2 2023 Aug 09, 2023	SELL	$1.21 - $2.08 $26,926 - $46,286	-22,253 Reduced 33.32%	44,532 $77,000
Q1 2023 May 12, 2023	SELL	$1.25 - $4.05 $9,366 - $30,346	-7,493 Reduced 10.09%	66,785 $84,000
Q4 2022 Feb 09, 2023	BUY	$0.57 - $3.03 $42,338 - $225,062	74,278 New	74,278 $225,000
Q2 2022 Aug 12, 2022	SELL	$0.54 - $1.15 $146,409 - $311,798	-271,129 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.0 - $1.58 $293,259 - $463,349	-293,259 Reduced 51.96%	271,129 $309,000
Q4 2021 Feb 09, 2022	SELL	$1.44 - $2.14 $489,945 - $728,113	-340,240 Reduced 37.61%	564,388 $813,000
Q3 2021 Nov 12, 2021	SELL	$1.8 - $2.39 $493,758 - $655,600	-274,310 Reduced 23.27%	904,628 $1.98 Million
Q2 2021 Aug 12, 2021	SELL	$2.16 - $3.18 $77,001 - $113,363	-35,649 Reduced 2.94%	1,178,938 $2.74 Million
Q1 2021 May 14, 2021	BUY	$2.89 - $4.22 $18,689 - $27,290	6,467 Added 0.54%	1,214,587 $3.66 Million
Q4 2020 Feb 25, 2021	BUY	$2.69 - $4.24 $3.25 Million - $5.12 Million	1,208,120 New	1,208,120 $4.54 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.